Sugi Predict

Sugi Predict / Targets / CFH

CFH

Complement factor H · P08603 · CFH on Sugi Atlas →

173 patent compounds predicted against CFH, 144 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Hydrochloric Acid Hydrochloric Acid (SCHEMBL29377504) 1.00 1/20
SCHEMBL3052253 SCHEMBL3052253 0.98 1/20
SCHEMBL29825652 SCHEMBL29825652 0.98 1/20
SCHEMBL31067656 SCHEMBL31067656 0.98 1/20
SCHEMBL7742478 SCHEMBL7742478 0.87 1/20
SCHEMBL13550922 SCHEMBL13550922 0.86 1/20
SCHEMBL7749603 SCHEMBL7749603 0.83 1/20
SCHEMBL19706432 SCHEMBL19706432 0.82 1/20
SCHEMBL14565395 SCHEMBL14565395 0.78 1/20
SCHEMBL14565397 SCHEMBL14565397 0.78 1/20
SCHEMBL3833378 SCHEMBL3833378 0.74 1/20
SCHEMBL4350425 SCHEMBL4350425 0.74 1/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL3833242) 0.70 1/20
SCHEMBL8163627 SCHEMBL8163627 0.69 1/20
SCHEMBL27536938 SCHEMBL27536938 0.69 1/20
SCHEMBL31678809 SCHEMBL31678809 0.69 1/20
SCHEMBL7746996 SCHEMBL7746996 0.68 1/20
SCHEMBL3832849 SCHEMBL3832849 0.64 1/20
SCHEMBL14318599 SCHEMBL14318599 0.64 1/20
SCHEMBL18604666 SCHEMBL18604666 0.64 1/20

Clinical trials — most relevant to CFH by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC GENERIUM, Russian Federation) PHASE3COMPLETED
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria PHASE3COMPLETED
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria PHASE3COMPLETED
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI PHASE1/PHASE2COMPLETED
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) PHASE2COMPLETED
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms PHASE2COMPLETED
TP10 Use in Patients With C3 Glomerulopathy (C3G) PHASE1WITHDRAWN
Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration PHASE1COMPLETED
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy PHASE1COMPLETED
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers PHASE1COMPLETED
First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers PHASE1COMPLETED
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD nanCOMPLETED
The Association of the Peripheral Retinal Changes and Genotypic Changes in Patients With Age Related Macular Degeneration nanCOMPLETED
Genetic Load and Phenotype in Aggressive AMD nanCOMPLETED
Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid? nanCOMPLETED
DKK-3 rs11544814 and CFH rs10737680 Polymorphism and Protein Levels With Non Surgical Periodontal Therapy in Periodontitis Patients With and Without CAD nanUNKNOWN
Assessment of Disease Severity, Progression and Treatment in Infected Patients Presenting to the Emergency Department nanCOMPLETED
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration nanCOMPLETED
Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs nanCOMPLETED
Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population nanUNKNOWN
Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV) nanCOMPLETED
Investigating Meningococcal Vaccines in Adults nanCOMPLETED
Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria® nanCOMPLETED
Proadrenomedullin for Early Risk Assessment in the Emergency Department nanCOMPLETED
Role of Renal Artery Doppler in Critically Ill Children With Acute Kidney Injury nanUNKNOWN
Complement and Graft-versus-host Disease nanCOMPLETED
Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion nanCOMPLETED
The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria nanCOMPLETED
Association of Previously Verified Gene Polymorphisms With AMD in Turkish Population nanUNKNOWN
Effect of Platelet Storage on Complement Activation nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CFH binder may also engage these)

ProteinNameSimilarity
P06909 — 0.984 P06909 →
Q02985 — 0.978 Q02985 →
Q03591 — 0.978 Q03591 →
Q9BXR6 — 0.972 Q9BXR6 →
P36980 — 0.969 P36980 →
Q28085 — 0.966 Q28085 →
P49457 — 0.944 P49457 →
O19124 — 0.942 O19124 →
P08174 — 0.934 P08174 →
Q2VPA4 — 0.931 Q2VPA4 →
Q6VE48 — 0.928 Q6VE48 →
O02839 — 0.918 O02839 →
O62685 — 0.915 O62685 →
Q5R4D0 — 0.912 Q5R4D0 →
P04003 — 0.906 P04003 →
O62837 — 0.905 O62837 →
P79138 — 0.902 P79138 →
P97528 — 0.900 P97528 →
Q92496 — 0.899 Q92496 →
Q63514 — 0.898 Q63514 →
P15529 — 0.898 P15529 →
Q63135 — 0.897 Q63135 →
Q9JMB8 — 0.896 Q9JMB8 →
Q07968 — 0.896 Q07968 →
Q28065 — 0.894 Q28065 →
Q14246 — 0.894 Q14246 →
Q9UQ52 — 0.893 Q9UQ52 →
F13B Coagulation factor XIII B chain 0.892 landscape →
Q8HYX8 — 0.890 Q8HYX8 →
Q9NPH3 — 0.888 Q9NPH3 →